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Exposure of platelets to toxins (calyculin A or okadaic acid) that inhibit protein serine/threonine phosphatases types 1 and 2A, at
concentrations that block aggregatory and secretory responses, results in the phosphorylation of several platelet proteins including integrin β3.
Since protein phosphorylation represents a balance between kinase and phosphatase activities, this increase in phosphorylation reflects either the
removal of phosphatases that oppose constitutively active kinases known to reside in the platelet (e.g., casein kinase 2) or the activation of
endogenous kinases. In this study, we demonstrate that the addition of calyculin A promotes the activation of several endogenous platelet protein
kinases, including p42/44mapk, p38mapk, Akt/PKB, and LKB1. Using a pharmacologic approach, we assessed whether inhibition of these and other
enzymes block phosphorylation of β3. Inhibitors of p38
mapk, casein kinase, AMP kinase, protein kinase C, and calcium–calmodulin-dependent
kinases did not block phosphorylation of β3 on thr
753. In contrast, 5′-iodotubercidin, at 50 μM, blocks β3 phosphorylation without affecting the
efficacy of calyculin A to inhibit platelet aggregation and spreading. These data dissociate threonine phosphorylation of β3 molecules and
inhibition of platelet responses by protein phosphatase inhibitors.
© 2006 Elsevier B.V. All rights reserved.Keywords: Platelet; Calyculin A; Phosphatase; Integrin; Iodotubercidin1. Introduction
A correlation between protein seryl/threonyl phosphoryla-
tion and platelet activation was first demonstrated in [32P]
orthophosphate-labeled platelets by Lyons and coworkers, who
found that thrombin promoted a two- to six-fold increase in
incorporation of 32P into pleckstrin and myosin light chains [1].
These changes correlate in a time- and dose-dependent fashionAbbreviations: AMPK, AMP-activated protein kinase; ARA-A, adenine-9-
β-D-arabino-furanoside; CK, casein kinase; GSK, glycogen synthase kinase;
HRP, horseradish peroxidase; hsp, heat shock protein; kDa, kilodalton; MAP,
mitogen activated protein; MEK, MAPK/ERK kinase; PDK, 3-phosphoinosi-
tide-dependent kinase; PK, protein kinase; PP1, protein phosphatase type 1;
PP2A, protein phosphatase type 2A; PRK, PKC-related protein kinase; SDS
PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; ser, serine;
SGK, serum- and glucocorticoid-induced kinase; thr, threonine; tyr, tyrosine;
VASP, vasodilator-stimulated phosphoprotein
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have been suggested to regulate phosphorylation/dephosphor-
ylation reactions within platelets. The majority of protein serine/
threonine kinases identified in platelets are associated with a
signaling circuitry involved in triggering specific responses.
Included in, but not limited to this group are PKC family
members (α, β, δ, ε, η, θ, ζ), p38mapk, p44/42mapk, Akt/PKB,
and myosin light chain kinase [2–11]. Only select protein
kinases have been found to dampen platelet responses,
including PKA and PKG, although recent data supports the
notion that PKG is involved in the activating pathway [12].
Few advances have been made toward understanding where
protein serine/threonine phosphatases fit in with respect to the
signaling circuitry that controls platelet reactivity. Four types of
protein serine/threonine phosphatases are found in platelets:
PP1 (myosin light-chain phosphatase), PP2A, PP2B (calci-
neurin), and PP2C [13–16]. Although the functions of each of
these enzymes remain elusive, two lines of evidence implicate
PP1 and PP2A in the circuitry that triggers platelet responses.
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membrane permeable inhibitors of these enzymes, block
platelet secretions and aggregation [16,17]. Second, the
catalytic subunits of these enzymes, PP1c and PP2Ac,
redistribute to distinct cellular fractions as a consequence of
platelet activation. For example, soluble forms of PP1c and
PP2Ac are found in the resting platelet [16] and treatment with
agonists promotes their association with cytoskeletal structures
suggesting a link between these enzymes and platelet responses
[18]. In resting platelets, PP1c is also found complexed with
other proteins including heat shock proteins (hsp) [19],
phosphatase-binding regulatory subunits [20] and αIIb [21].
Adhesion to collagen or engagement of αIIbβ3 with fibrinogen
promotes the release of PP1c from hsp complexes and αIIb,
respectively, correlating with the dephosphorylation of PP1c
substrates such as myosin light chains. A decrease in apparent
serine/threonine phosphatase activity affects α-granule secre-
tion, indicating that activation of these enzymes is part of the
circuitry that defines normal platelet reactivity [22].
In the absence of an agonist, the addition of calyculin A or
okadaic acid results in the phosphorylation of several platelet
proteins, including myosin light chain [23], proteins with
molecular weights corresponding to 14.4, 25, 32, 36, 50–52,
57–60, 74–80, 210, and 230 kDa [24,25], phospholipase A2
[24], talin [26], VASP [27], and integrin β3 subunit [28].
Although these phosphorylations collectively correlate with
platelet inhibition, suggesting that PP1 and PP2A are part of the
circuitry needed for platelet activation, the role that these
individual phosphorylation events play in blocking platelet
responses is unclear. Hence, the biological consequence of each
of these phosphorylations remains to be determined and any
suggestion that they mediate the inhibitory effects of phospha-
tase inhibitors are solely correlative. For example, although
phosphorylation of integrin β3 on threonine 753 (thr
753)
correlates with an inhibition of outside-in integrin signaling
[29], studies have not definitively demonstrated that this
modification is required to negatively modulate platelet
functions. To determine whether this phosphorylation event is
sufficient or essential for inhibiting platelet responses, we set
out to inhibit threonyl phosphorylation of β3 and assess whether
platelet responses remain inhibited in the presence of calyculin
A. Here we report that sustained phosphorylation β3 on thr
753 is
not necessary for phosphatase inhibitors to block platelet
aggregations, spreading, and secretions.
2. Materials and methods
2.1. Materials
ARA-A, apyrases, bovine serum albumin, 2-mercaptoethanol, and prosta-
glandin E1, were obtained from Sigma. Calbiochem supplied the following
inhibitors (target enzyme indicated in parentheses): ERK activation inhibitor
peptide II (p42mapk), GÖ6938 (PKC), IC261 (AMP kinase), 5′-iodotubercidin
(p42mapk), PD98059 (MEK), SB203580 (p38mapk), 1L-6-Hydroxymethyl-chiro-
inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate (Akt/PKB), Akt Inhibitor X
(Akt/PKB), and Akt Inhibitor VIII (Akt/PKB). Calyculin A and okadaic acid
were purchased from Alexis Biochemicals. The following antibodies were
purchased from (i) Cell Signaling: rabbit anti-LKB1, rabbit anti-phospho-LKB1,
rabbit phospho-PDK1 (ser241), rabbit phospho-PKCζ/λ (thr410/403), rabbit non-phospho-Akt/PKB, rabbit phospho-Akt/PKB (ser473), rabbit phospho-Akt/PKB
(thr308), (ii) Stressgen: rabbit anti-hsp27, rabbit anti-hsp27(phospho78) (iii)
Sigma: monoclonal anti-MAP kinases, activated diphosphorylated ERK1 and
ERK2, and rabbit anti-MAP kinase. Acrylamide, N′,N′-methylene bisacryla-
mide, low molecular weight prestained standards, non-fat dried milk, and HRP-
conjugated goat anti-rabbit and anti-mouse IgGs were purchased from Bio-Rad.
Amersham Pharmacia Biotech supplied the enhanced chemiluminescence assay
kit. Upstate Biochemical Institute supplied active Akt/PKB. Phosphorylated and
non-phosphorylated peptides that mimic the cytosolic portion of β3 (LYKEATS
[pT]FTNITYR, LYKEATSTFTNITYR, KEATSTFTNIT[pY]RGT), peptide
affinity matrices, and anti-phospho-β3 antibody were generated by Sigma
Genosys Biotechnologies, Inc. (Woodlands, TX). Anti-β3 monoclonal antibody
(7E3), PDK1 chemical inhibitor (OSU-03012), and thrombin were gifts from
Drs. Barry Coller (Rockefeller University, NY), Ching-Shih Chen (Ohio State
University, OH) and Walter Kisiel (University of New Medico, Albuquerque,
NM), respectively.
2.2. Platelet preparations
Procedures for isolating platelets from human blood were conducted at
21 °C. Blood (10 parts) was drawn into vacutainer tubes containing acid-citrate-
dextrose (1 part). Platelet-rich plasma, obtained by centrifugation at 110×g for
10 min, was treated with prostaglandin E1 (0.4 μM) and apyrases (12.5 milli-
units/mL) and centrifuged at 1100×g for 15 min. The resulting platelet pellet
was suspended in a platelet wash buffer containing 5 mM HEPES, pH 6.4,
140 mM NaCl, 1 mM MgCl2, 2 mM KCl, 5.5 mM glucose, 12 mM NaHCO3,
0.2% (w/v) bovine serum albumin, 0.2 μM prostaglandin E1, and apyrases
(6 milliunits/mL), and recentrifuged at 1100×g for 15 min. Platelets were
suspended in a final suspension buffer containing 10 mM HEPES, pH 7.4,
140 mM NaCl, 1 mM MgCl2, 2 mM KCl, 5.5 mM glucose, and 12 mM
NaHCO3 at a concentration of 2×10
9/mL.
2.3. Antibody generation and characterization
Anti-phospho-β3 antibody was raised in rabbits against the synthetic peptide
LYKEATS[pThr]FTNITYR corresponding to amino acids 746–760 of β3. Anti-
phospho-β3 antibodies were affinity purified by sequential fractionation through
columns containing agarose linked to unphosphorylated and thr753-phosphor-
ylated peptides. Several lines of evidence (not shown) demonstrate that the
polyclonal antibody specifically recognizes β3 phosphorylated at thr
753. First,
using assay conditions in which β3 is stoichiometrically phosphorylated at thr
753
[28], the antibody recognized β3 solubilized from calyculin A-treated platelets.
As expected, the immunoreactive β3 migrates as a 106 kDa protein on reducing
gels, and as a 96 kDa protein under non-reducing conditions. Second,
immunodetection of phospho-β3 was blocked if the antibody was first pretreated
with the phosphopeptide used for its generation, but not if pretreated with non-
phosphorylated, tyrosyl-phosphorylated peptides or peptides containing a
phosphate group on thr751. Third, phospho-β3 was immunologically detected
in platelets using similar incubation times needed for calyculin A to affect
platelet functions and the incorporation of [32P]orthophosphate into platelet
proteins (30). Fourth, phospho-β3 was immunoprecipitated from calyculin A-
treated platelets using 7E3, an antibody that detects intact αIIbβ3 complexes
[31]. These data strongly suggest that phospho-β3 is part of the intact integrin
complex. Lastly, using a solid support-based phosphatase assay [32],
dephosphorylation of β3 on nitrocellulose membranes with PP2A abolished
immunodetection, demonstrating the phosphorylation dependency of the
antibody.
2.4. Platelet aggregations
300 μL of a platelet suspension (0.5×109/mL) were treated with buffer,
calyculin A (100 nM), or thrombin (0.2 units/mL) for the indicated times at
37 °C while stirring at 800 rpm in a Chronolog Lumiaggregometer. Reactions
were quenched by the addition of SDS-PAGE gel buffer (20 mM Tris–HCl, pH
6.8, 1% SDS, 10% glycerol, 5% 2-mercaptoethanol, 2 mM EGTA, 0.05%
bromophenol blue) for direct Western analysis. In studies that make use of
specific protein kinase inhibitors, platelets were pretreated with each inhibitor 5
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follows: iodotubercidin, 50 μM; ARA-A, 2 mM; PD98059, 10 μM; ERK-
activating inhibitory peptide, 10 μM; SB203580, 10 μM; IC261, 10 μM.
2.5. SDS-PAGE and Western analysis
Proteins were separated on either 6.5% or 10% SDS-polyacrylamide gels
followed by transfer to nitrocellulose membranes for 1 hour at 100 V.
Membranes were blocked with Tween 20-containing Tris-buffered saline
containing 5% non-fat dried milk and incubated overnight at 4 °C with the
following antibodies at a dilution of 1:1000: anti-phospho-β3, anti-MAP kinase,
anti-activated MAP kinase, anti-phospho-hsp27, anti-phospho Akt/PKB
(Thr308), anti-phospho-Akt/PKB (Ser473), anti-non-phospho-Akt/PKB, anti-
phospho-LKB1, anti-phospho-PKCζ, anti-PKCζ, or anti-phospho-PDK1.
Incubations were followed by incubating with an HRP-coupled goat anti-rabbit
or anti-mouse antibody for 1 h at 21 °C. Immunoreactivity was detected using an
ECL detection kit. To quantitate relative changes in reactivity, densitometry
measurements were attained using an IS-1000 Digital Imaging System from
Alpha Innotech Corp. (San Leandro, CA).Fig. 1. Calyculin A activates MAP kinases. Washed platelets were
preincubated with or without the indicated protein kinase inhibitors prior to
the addition of 0.1 μM calyculin A (CAL-A) or 0.2 units/mL α-thrombin (IIa).
Following a 5-min incubation period, reactions were stopped by the addition
of SDS sample buffer and proteins separated on 10% polyacrylamide gels.
Western analyses were conducted using antibodies that recognize the active,
doubly phosphorylated forms of p42/p44MAP kinase (panel A, top Western),
non-active (total) p42/44mapk (panel A, lower Western), the active phosphor-
ylated form of p38mapk (panel B, top Western), non-active p38mapk (panel B,
lower Western), hsp27 phosphorylated on ser78 (panel C, top Western), and
total hsp27 (panel C, lower Western). The inhibitors added were 50 μM 5′-
iodotubercidin (Iodo), 2 mM ARA-A (ARA), 10 μM PD98059 (PD), 50 μM
ERK activation inhibitory peptide II (ERK), 10 μM SB20580 (SB), and
50 μM IC261(IC). Each Western blot is representative of 3 separate
experiments.3. Results
Phosphorylation represents a balance between protein
kinase and phosphatase activities, and inhibition of protein
phosphatases will promote phosphorylation if the opposing
kinase is active or becomes active in the presence of
phosphatase inhibitors. To identify compounds that may
potentially inhibit phosphorylation of thr753, we examined
the effect of calyculin A on the apparent activation of cellular
protein serine/threonine kinases that either are part of signaling
cascades that control platelet reactions (i.e., p42/44mapk and
p38mapk) or target the sequence motif (TSTF) that contains
thr753 and is common to other phosphoproteins (Table 1).
Protein kinases that target this consensus sequence include
AKT/PKB, PKCζ, and LKB1.
3.1. Calyculin A-treatment of platelets leads to the activation of
MAP kinases: sensitivity to inhibitors of MEK (PD98059),
p42mapk (iodotubercidin), p38mapk (SB203580), casein kinase I
(IC261), and AMP-activated protein kinase (Ara-A)
Incubating platelets with calyculin A increased the apparent
activities of p42/44mapk as assessed by Western analysis using
an antibody to detect active dual- phosphorylated forms of the
enzymes (Fig. 1, panel A). This activation is partially sensitive
to 10 μM PD98059, a MEK inhibitor, and insensitive to an
inhibitory peptide that blocks MEK–ERK interactions, indicat-
ing that p42/44mapk activation by calyculin A is independent of
MEK activity. In contrast, PD98059 blocks p42/44mapkTable 1
Conservation of TSTF motifs in cellular protiensactivation in thrombin-stimulated platelets, illustrating that
calyculin A stimulates p42/44mapk in a manner distinct from that
of thrombin. While it has been suggested that MAP kinase
activity may be regulated, in part, by autophosphorylation [33],
we demonstrate that calyculin A treatment of platelets leads to
MAP kinase activation in the presence of 5′-iodotubercidin, a
promiscuous inhibitor that targets p42mapk, AMPK, and CKI
[34,35]. We often control for the effects of 5′-iodotubercidin on
AMPK and CKI activities by using ARA-A and IC261,
Fig. 3. Calyculin A activates LKB1. Washed platelets were treated with buffer
(control) or 0.1 μM calyculin A (CAL-A) for 5 min prior to the addition of SDS
sample buffer. SDS-solubilized proteins were separated on 10% polyacrylamide
gels and Western analyses conducted using anti-non-phospho- and anti-
phospho-LKB1 antibodies. The arrow points to the position of LKB1. A yet-
to-be identified higher molecular weight band is also routinely visualized. Each
Western analysis is representative of 3 separate experiments.
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MAP kinase activation in platelets exposed to calyculin A.
The addition of calyculin A also led to the apparent
activation of p38mapk, correlating with the phosphorylation of
p38mapk and one of its substrates, hsp27 (Fig. 1, panels B and
C). The addition of 10 μM SB203580, a highly selective
inhibitor to p38mapk, blocked hsp27 phosphorylation without
affecting p38mapk and p42/p44mapk activation. Overall, these
studies indicate that calyculin A activates several members of
the MAP kinase family of protein kinases.
3.2. Calyculin A-treatment of platelets leads to activation of
kinases known to target TSTF motifs
A second approach was to study protein kinases that have
overlapping substrate specificity and that target critical
phosphorylation consensus sites that mimic residues 751–754
(751TSTF) in β3. As seen in Table 1, this motif is conserved in a
variety of proteins, including GSK3, an enzyme involved in the
Wnt signaling pathway, protein translation, and cell polarity
[36], and members of the AGC kinases family, including SGK,
PRK2, and PKCζ. Enzymes that target these motifs include Akt/
PKB, PKCζ, and LKB1 [37]. To assess whether Akt/PKB and
its upstream activating kinase, PDK1, are activated in calyculin
A-treated platelets, we examined the phosphorylation state of
the consensus serine/threonine residues of the activation loops
(Ser241 of PDK1 and Thr308 in Akt/PKB) and of Ser473 in the C-
terminal portion of Akt/PKB. As previously shown, calyculin A
treatment consistently results in the phosphorylation of Ser473
within Akt/PKB without changing the levels of Akt/PKB in
platelets (Fig. 2, panel A). Thr308 also becomes phosphorylated
(Fig. 2, panel A), suggesting that calyculin A is increasing the
apparent activity of PDK1 [38]. PDK1, however, appears to be
constitutively active in that Ser241 is phosphorylated in naïve
circulating platelets: The addition of calyculin A (Fig. 2, panel
B) or thrombin (data not shown) does not augment theFig. 2. PDK1 is constitutively active in platelets whereas calyculin A activates
Akt/PKB. Washed platelets were incubated with buffer (control) or calyculin A
(CAL-A) for 5 min prior to the addition of SDS sample buffer. Proteins were
separated by 10% polyacrylamide gels and Western analyses conducted using
antiserum that recognizes total Akt/PKB, Akt/PKB phosphorylated on ser308, or
Akt/PKB phosphorylated on thr473 (panel A), or PDK1 phosphorylated on
ser241(panel B). The Western analyses are representative of 4–12 separate
experiments.phosphorylation of PDK1. Together, these data suggest that
endogenous platelet PDK1 is active and the phosphorylation
state of its target proteins depends on protein phosphatase
activity.
To assess the activation states of LKB1 and PKCζ in
platelets, we examined the phosphorylation state of site
Thr189 in LKB1 and Ser409 in the consensus activation loop
of PKCζ. Calyculin A treatment of platelets stimulated the
phosphorylation of LKB1 on thr189, raising the possibility
that LKB1 activation leads to β3 phosphorylation (Fig. 3).
PKCζ is expressed in platelets and migrates as a doublet at
approximately 80 kDa; we do not find, however, increased
phosphorylation of PKCζ following the addition of calyculin
A (data not shown), ruling out the possibility that PKCζ is
targeting thr753 in β3.
3.3. 5′-Iodotubercidin dissociates β3 phosphorylation from
thrombin and calyculin A effects
Together, the above data indicate that calyculin A treatment
activates numerous kinases within platelets, explaining its
pleiotropic effects on platelet responses. We next tested the
ability of kinase inhibitors to block threonine-phosphorylation
of β3 using a phosphorylation-state specific antibody that
detects β3 phosphorylated on thr
753 (see Materials and
methods). The above data indicate that p38mapk, p42/44mapk,
and LKB1 are activated by calyculin A. A possible role for the
MAP kinases was explored using a pharmacological approach.
Although SB203580 blocks hsp27 phosphorylation, it did not
affect calyculin A-induced β3 phosphorylation, indicating that
p38mapk does not target β3 (Fig. 4). This places this inhibitor
into a family of reagents that we find to be ineffective in
blocking β3 phosphorylation, including PD 98059 (10μM;
MEK inhibitor, Fig. 4), ERK activation inhibitory peptide (Fig.
4), bisindolylmaleimide (1 μM; PKC inhibitor), GÖ6983
(1 μM; PKCζ inhibitor), KN93 (0.5 μM; calmodulin-dependent
kinase inhibitor), 5,6-dichloro-1-β-D-ribofuranosylbenzimida-
Fig. 5. 5′-Iodotubercidin does not block platelet aggregation or the ability of
calyculin A (CAL-A) to block aggregation. Washed platelets were treated with
either buffer (curves A, D, G) or 5′-iodotubercidin (Iodo) (5 μM, curves B and
E; 50 μM, curves C, F, H) prior to the addition of 0.2 units/mL thrombin (IIa)
(curves A–C) or 0.1 μM calyculin A (curves D–H). As shown in curves G and
H, thrombin was added following the addition of calyculin A.
Fig. 4. β3 phosphorylation is inhibited by 5′-iodotubercidin. Washed platelets
were pretreated with buffer (control) or the indicated inhibitor at concentrations
discussed in Fig. 1. Following the addition of 0.1 μM calyculin A (CAL-A),
reactions were quenched and proteins separated on 6.5% polyacrylamide gels.
Western analyses were conducted using anti-phospho-β3 antiserum that
recognizes β3 phosphorylated on thr
753.
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PI3 kinase inhibitor). In contrast, iodotubercidin is a potent
inhibitor of β3 phosphorylation: 5′-Iodotubercidin at 50 μM
blocks phosphorylation of thr753 (Fig. 4). As discussed above,
5′-iodotubercidin inhibits ERK2, AMPK, and CKI. ARA-A
(Fig. 4), and IC261 (data not shown) did not block β3
phosphorylation, indicating that the effects of calyculin A are
not being mediated by activation of AMPK or CKI.
To investigate whether calyculin A-induced phosphoryla-
tion of β3 on thr
753 is exclusively needed for inhibiting
platelet functions, we examined how 5′-iodotubercidin
affects the response of platelets to thrombin and calyculin
A. As seen in Fig. 5, thrombin-induced platelet aggregation
was not changed by the addition of the kinase inhibitor
(curves A–C). Similarly, 5′-iodotubercidin did not block
calyculin A-induced platelet shape change (curves D–F) or,
at concentrations that inhibit β3 phosphorylation, prevent the
efficacy of calyculin A in inhibiting platelet aggregation
(curves G and H) or spreading on fibrinogen matrices (data
not shown). Together, these data dissociate threonine
phosphorylation of β3 and inhibition of platelet responses
by phosphatase inhibitors.
4. Discussion
Posttranslational events are extremely important in regulat-
ing platelet reactivity. In particular, protein phosphorylation
signaling cascades are triggered by both agonists and
antagonists and several protein serine/threonine kinases have
been found to be regulators of platelet reactions. Protein serine/
threonine phosphatase activities also appear to be important
based primarily on the observations that calyculin A and
okadaic acid block platelet responses. The addition of these
inhibitors leads to increased phosphorylation of numerous
platelet proteins; the specific phosphorylation that is responsible
for inhibiting individual platelet responses is not known.We hypothesized that β3 phosphorylation is part of a
dynamic braking mechanism that regulates the progression of
events linked to integrin signaling. Stable threonine phos-
phorylation of β3 prevents aggregation-dependent cytoskeletal
rearrangement [17] and adhesion-dependent cell spreading
[28]. Adding calcium ionophore to calyculin A-treated
platelets promotes its dephosphorylation and restores platelet
spreading on a fibrinogen matrix [28]. These data suggest a
potential regulatory mechanism by which transient threonine
phosphorylation regulates integrin function. The negative
effect that phosphorylation of thr753 has on αIIbβ3 is akin to
how transient phosphorylation negatively controls the activa-
tion of cellular enzymes such as cyclin-dependent kinases
[39].
Although stable threonine phosphorylation of site 753 has
been implicated in impairing β3 functions, it is only obtained by
inhibiting cellular PP1 and PP2A with either calyculin A or
okadaic acid. It is unlikely, however, that the effects of these
phosphatase inhibitors are due to the phosphorylation of a single
protein. Several proteins show marked increases in [32P]-
labeling following the addition of calyculin A and okadaic acid
[25,30]. Conventional approaches fail to identify other
increases, which may account for calyculin A and okadaic
acid effects. This includes β3 itself, which was identified as a
phosphorylated protein using immunoprecipitation procedures
[28]. Thus, experiments need to examine whether a specific
phosphorylation/dephosphorylation reaction plays a key role in
cellular functions. To evaluate the function of β3 phosphory-
lation with respect to platelet aggregation, we set out to identify
kinases that potentially target site 753.
We recognize that treatment of platelets with calyculin A
may be affecting kinase activities that have yet to be defined
within the platelet. For example, we identified LKB1 in platelets
and found it to be phosphorylated following the addition of
calyculin A, not thrombin. LKB1 is part of a kinase cascade that
acts as a sensor of altered ATP levels [40] and regulates Wnt
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investigated. Calyculin A does increase the activation state of
several obvious candidates, including members of the MAP
kinase family and Akt/PKB. p42/44mapk and p38mapk are
presumably activated following thrombin treatment [41]. p42/
44mapk become associated with the platelet cytoskeleton in
thrombin-stimulated platelets, placing them in close proximity
to β3 [42]. Interestingly, p42
mapk is negatively regulated as a
consequence of integrin engagement [43], most likely due to
dephosphorylation of thr183 [44]. The addition of okadaic acid
restores p42mapk phosphorylation in aggregated platelets [44].
Together, these data are consistent with p42mapk targeting β3.
However, ERK2 does not phosphorylate intact native β3 or
denatured β3 using in vitro kinase assays (Venjara and Lerea,
data not shown).
5′-Iodotubercidin is a general protein kinase inhibitor that
has been shown to target p42mapk, CKI, and AMPK [34,35]. 5′-
Iodotubercidin, at concentrations greater than 50 μM, will also
inhibits Akt/PKB in vitro (Kelly and Lerea, data not shown). We
may speculate that β3 phosphorylation depends on activated
Akt/PKB and repressed PP1/PP2A activity. In support of this
hypothesis, β1, Akt/PKB, and a subpopulation of PP2A have
been shown to associate together [45], raising the possibility
that increased PP2A activity represses Akt/PKB activity,
keeping β subunits in a dephosphorylated state. Not in
agreement of this hypothesis is that selective inhibitors against
Akt/PKB (1L-6-Hydroxymethyl-chiro-inositol 2-(R)-2-O-
methyl-3-O-octadecylcarbonate; Akt Inhibitor X; Akt Inhibitor
VIII) and PDK1 (OSU-03012) did not block calyculin A-
induced phosphorylation of β3 (data not shown).
Using 5′-iodotubercidin, we have shown that phosphoryla-
tion of β3 on thr
753 is not required for calyculin A or okadaic
acid to exert a negative effect on platelets with respect to
aggregation. It is still an open question as to the role of these
phosphorylation events in controlling platelet adhesion and
spreading. Previous data suggest that phosphothreonine will not
block tyrosine phosphorylation of β3, but will prevent the
association of shc to the activated integrin complex [29]. This,
in turn, will block cytoskeletal rearrangements necessary for the
spreading of adhered platelets and retraction of clots. It remains
possible that threonine phosphorylation of β3 is a mechanism
by which αIIbβ3 molecules on adhered platelets remain locked
in a low affinity state, allowing platelets to roll over denuded
surfaces prior to attachment [46]. We are currently evaluating
this hypothesis using β3 mutants in which thr
753 has been
replaced by an aspartate residue.
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